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Degradation
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Young-Ho Park1 and Kyung-Min Lim1,2
Liver X receptors (LXRs) are nuclear receptors that act as ligand-activated transcription factors regulating lipid
metabolism and inflammation. In the skin, activation of LXRs stimulates differentiation of keratinocytes and
augments lipid synthesis in sebocytes. However, the function of LXRs in melanocytes remains largely unknown.
We investigated whether LXR activation would affect melanogenesis. In human primary melanocytes, MNT-1, and
B16 melanoma cells, TO901317, a synthetic LXR ligand, inhibited melanogenesis. Small interfering RNA (siRNA)
experiments revealed the dominant role of LXRb in TO901317-mediated antimelanogenesis. Enzymatic activities
of tyrosinase were unaffected, but the expression of tyrosinase, tyrosinase-related protein-1 (TRP-1), and TRP-2
was suppressed by TO901317. Expressions of microphthalmia-associated transcription factor (MITF), a master
transcriptional regulator of melanogenesis, and cAMP-responsive element-binding activation were not affected. It
is noteworthy that the degradation of MITF was accelerated by TO901317. Extracellular signal–regulated kinase
(ERK) contributed to TO901317-induced antimelanogenesis, which was evidenced by recovery of melanogenesis
with ERK inhibitor. Other LXR ligands, 22(R)-hydroxycholesterol (22(R)HC) and GW3965, also activated ERK and
suppressed melanogenesis. The intermediary role of Ras was confirmed in TO901317-induced ERK phosphoryla-
tion. Finally, antimelanogenic effects of TO901317 were confirmed in vivo in UVB-tanning model in brown
guinea pigs, providing a previously unreported line of evidence that LXRs may be important targets for
antimelanogenesis.
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INTRODUCTION
Liver X receptors (LXRa/NR1H3 and LXRb/NR1H2) are ligand-
activated nuclear receptors that have pivotal roles in lipid
metabolism and cholesterol homeostasis (Castrillo and
Tontonoz, 2004). LXRa is highly expressed in the liver,
whereas LXRb is more ubiquitous (Pru¨fer and Boudreaux,
2007). Both isoforms are activated by endogenous oxysterols,
such as 22(R)-hydroxycholesterol (22(R)HC) and 24(S)-
hydroxycholesterol, and synthetic ligands, such as
TO901317 and GW3965 (Hu et al., 2010). LXR activators
induce the expression of genes involved in lipid metabolism,
cholesterol efflux, and transport, such as apolipoprotein E
(ApoE) and ATP-binding cassette protein A1 (ABCA1) (Zelcer
and Tontonoz, 2006). LXR activators also exhibit potent anti-
inflammatory activities in many inflammatory disorders,
including dermatitis, atherosclerosis, and pulmonary
inflammation, through the suppression of several NF-kB
target genes, such as inducible nitric oxide synthase, IL-6,
cyclooxygenase 2, matrix metalloproteinase 9, CCL2, CCL7,
and IL-1b (Bensinger and Tontonoz, 2008).
LXRs are also expressed in the skin tissues such as
sebaceous glands, hair follicle, epidermal keratinocytes,
and fibroblast (Hanley et al., 1999; Billoni et al., 2000;
Russell et al., 2007). LXR activation induces keratinocyte
differentiation and inhibits proliferation (Ko¨mu¨ves et al.,
2002). Topical treatment of LXR activators improves
epidermal permeability barrier homeostasis (Man et al.,
2006) and manifests anti-inflammatory effects in irritant
and allergic contact dermatitis models (Fowler et al., 2003).
In addition, LXR activators stimulate lipid synthesis and
differentiation in sebocyte, while it reduces hair growth
(Russell et al., 2007; Hong et al., 2008). Recently, Kumar
et al. (2010) demonstrated that LXRs are also expressed in
melanocytes. Especially, they showed that LXRs are
upregulated in the melanocytes from perilesional skin of
vitiligo patients, suggesting that LXRs might be involved in
the regulation of melanin production. However, to the best
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of our knowledge, little is known about the effects of LXR
activation on melanogenesis.
Melanogenesis is the most important function of melano-
cytes in the skin. Melanin has a key role in the protection of
the skin from UV-induced damage. However, excessive
production of melanin results in hyperpigmentation, which
is represented as melasma, freckles, and dark spots (Jadotte
and Schwartz, 2010). Three key melanogenic enzymes,
tyrosinase, tyrosinase-related protein-1 (TRP-1), and (TRP-2),
participate in melanogenesis (Ko¨rner and Pawelek, 1982;
Kameyama et al., 1993). Tyrosinase is the rate-limiting
enzyme that catalyzes two critical steps in melanogenesis:
the hydroxylation of L-tyrosine to DOPA (3,4-
dihydroxyphenylalanine) and the subsequent oxidation of
DOPA into dopaquinine. TRP-2 catalyzes the DOPA chrome
to indol-5,6-quinone 2-carboxylic acid (DHICA), and TRP-1
catalyzes the oxidation of DHICA to carboxylated indole-
quinone (Hearing and Tsukamoto, 1991). Thus, the
upregulation or activation of melanogenic enzymes can
increase melanogenesis and hyperpigmentation.
Microphthalmia-associated transcription factor (MITF) is a
master transcription factor for melanogenesis. With a basic-
helix-loop-helix-leucine zipper (bHLHZip) structure, MITF
upregulates tyrosinase, TRP-1, and TRP-2 through binding to
an M-box motif in their promoter sites (Yasumoto et al., 1997).
MITF regulates melanocyte pigmentation, proliferation, and
survival (Steingrı´msson et al., 1994). Mutation of the MITF
gene in humans can cause abnormal pigmentation of the skin
and hair (Hughes et al., 1994; Tachibana, 2000). Moreover,
decreased MITF expression induces the downregulation of
melanocyte differentiation markers and inhibits melanogenesis
(Jime´nez-Cervantes et al., 2001). A key component for
MITF induction is the UV-mediated induction of the
proopiomelanocortin (POMC) and MC1 genes that encode
the a-melanocyte-stimulating hormone (a-MSH). a-MSH
binding to MC1R increases the intracellular levels of cAMP
(Corre et al., 2004) and activates protein kinase A, which
subsequently phosphorylates cAMP-responsive element-
binding (CREB) protein, an activator of MITF gene
expression. On the other hand, activation of extracellular
signal–regulated kinase (ERK) induces MITF phosphorylation
and degradation, ultimately suppressing melanogenesis (Wu
et al., 2000; Xu et al., 2000; Kim et al., 2003).
Here we examined whether LXR activation would affect
melanogenesis. Surprisingly, we found that a LXR activator,
TO901317, potently inhibits basal and a-MSH-, UV- and
ACTH-induced melanogenesis in human primary melano-
cytes, and MNT-1 and B16 melanoma cells. The underlying
mechanism was elucidated in the light of tyrosinase, TRP-1,
and TRP-2 expressions, and MITF modulation. Finally, the
antimelanogenic effects of TO901317 were confirmed in vivo
in UV-induced hyperpigmentation using brown guinea pigs.
RESULTS
TO901317-induced LXR activation inhibited melanin synthesis in
B16 murine melanoma cells
To investigate whether LXRs are expressed and activated by
TO901317 in B16 melanoma cells, we examined the
expression of LXR transcripts. Robust expression of LXRs was
confirmed by reverse transcription–PCR, and TO901317 sig-
nificantly induced ApoE, an exemplary target gene of LXR,
suggesting that LXRs are expressed and functional in murine
melanocytes (Figure 1a). Next, we determined the effect of
TO901317 on melanin synthesis by a-MSH. Both secreted and
cellular melanin contents were markedly reduced by
TO901317 in a dose-dependent manner (Figure 1b). Particu-
larly, the melanin concentration in dendrites and perinuclear
region, and the number and length of dendrites, were decreased
by TO901317 treatment (Figure 1c). TO901317 exerted no
cytotoxicity up to 10mM for 72 hours (data not shown).
Notably, 10mM TO901317 not only suppressed a-MSH-
induced melanin increase, but also significantly decreased the
basal melanin content. We further confirmed that these
antimelanogenic effects of TO901317 are also shown in
ACTH- or UVB-induced melanogenesis in B16 cells
(Figure 1d and e). The critical role of LXRb in TO901317-
mediated antimelanogenesis could be confirmed by the
application of small interfering RNAs (siRNAs) for LXRa and
LXRb (Figure 1f). Although the knockdown of LXRa did not
reverse the antimelanogenic effects of TO901317, TO901317
failed to manifest the antimelanogenic effects in the absence
of LXRb. These data revealed that LXR activation, especially
LXRb, inhibits melanin synthesis in melanocytes.
TO901317 inhibited the expression of melanogenic enzymes and
promoted MITF proteolysis
Tyrosinase activity is critical in melanogenesis. In line with the
antimelanogenic effects, TO901317 reduced cellular tyrosi-
nase activity by 60% (Po0.001) (Figure 2a). However, in
contrast to a positive control, kojic acid, TO901317 had no
direct inhibitory effect on the enzymatic activities of tyrosinase
(Figure 2b).
Melanin synthesis is regulated by three pivotal enzymes:
tyrosinase, TRP-1, and TRP-2. We determined whether the
inhibitory efficacy of TO901317 is related to the expression of
these enzymes. As shown in Figure 2c, TO901317 suppressed
the expression levels of tyrosinase, TRP-1, and TRP-2 in a dose-
dependent manner with or without a-MSH, reflecting that the
activation of LXRs suppressed melanogenesis by lowering the
expression of three key enzymes for melanin synthesis.
MITF is the common and major transcriptional regulator
governing the expression of pigment enzymes, tyrosinase,
TRP-1, and TRP-2. As shown in Figure 2d, MITF transcription
was increased by a-MSH. Unexpectedly, TO901317 did not
affect it, suggesting that LXR activation does not downregulate
MITF expression. Consistently, a-MSH-induced phosphoryla-
tion of CREB, a crucial transcription factor for the expression
of MITF gene, was not suppressed by TO901317 (Figure 2e).
To examine whether TO901317 will affect the translation of
MITF, western blot analysis was done with cell lysate after the
treatment with a-MSH. a-MSH increased the protein levels of
MITF, which peaked at 4 hours. The treatment of TO901317
did not decrease the protein levels of MITF at 4 hours,
suggesting that LXR activation does not affect the translation
of MITF (Figure 2f). Finally, we examined whether TO901317
can accelerate the degradation of MITF. MITF protein levels
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began to decrease at 8 hours after a-MSH treatment, which
were undetectable at 24 hours. Remarkably, MITF protein
rapidly decreased to undetectable levels at 8 hours in the
presence of TO901317 (Figure 2g), indicating that LXR
activation accelerates MITF protein degradation.
MEK/ERK/RSK signaling pathway is involved in TO901317-
induced MITF degradation
Concomitantly, with MITF upregulating cAMP/protein kinase A/
CREB pathway, the classical mitogen-activated protein kinase
(MAPK) pathway, which includes MAPK/ERK kinase (MEK),
ERK, and ribosomal S6 kinase (RSK), is operated following
MC1R activation. Activation of the ERK pathway induces MITF
degradation, which eventually dissipates melanogenic stimuli,
representing a major negative feedback mechanism (Hemesath
et al., 1998; Wu et al., 2000; Xu et al., 2000). Thus, we
examined whether TO901317 will affect the MAPK pathway.
As shown in Figure 3a, TO901317 induced the activation of the
MEK/ERK/RSK-1 signaling pathway. Furthermore, we found that
ERK activation by TO901317 was strongly enhanced in
a-MSH-stimulated B16 cells (Figure 3b).
Next, we determined whether ERK activation mediated the
antimelanogenic effects of TO901317 in a-MSH-stimulated
B16 cells. PD98059, a specific inhibitor of the MEK/ERK
pathway, suppressed ERK activation by TO901317 in B16
cells (Figure 3c). Notably, PD98059 reversed the inhibitory
effect of TO901317 on basal and a-MSH-induced melanogen-
esis significantly (Figure 4d).
We also tested whether the antimelanogenic effect of
TO901317 is shared by other LXR activators. A synthetic
LXR agonist, GW3965, and an endogenous ligand, 22(R)HC,
induced ERK activation at 5 minutes after their treatment, and
also inhibited melanin synthesis in a-MSH-stimulated B16
cells as TO901317 (Figure 4e), confirming that the activation
of LXRs inhibits melanogenesis in melanocytes through accel-
erating MITF degradation through the activation of the ERK
signaling pathway.
LXR activation also reduces melanogenesis in human
melanocytes in an ERK-dependent manner
The suppressive effect of TO901317 on melanogenesis was
also investigated in normal human primary melanocytes and
human melanoma cell line, MNT-1. Treatment of TO901317
to normal human melanocytes induced the expression of apoE
(Figure 4a), suggesting that LXR is well functioning in human
melanocytes. Consistent with the data from murine melanoma
cells, LXR activation also reduced the pigmentation in human
melanocytes, as determined by the decreased intensity of the
black color in cell pellet and lysates (Figure 4b) and reduced
melanin contents (Figure 4c).
Moreover, tyrosinase expression was suppressed and MITF
degradation was accelerated by the treatment of TO901317 in
human melanocytes (Figure 4d and e). As in B16 cells,
involvement of ERK activity in LXR-mediated antimelanogen-
esis was also confirmed (Figure 4f and g). Importantly, a small
GTPase protein, Ras, which is the upstream activator of
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MEK/ERK, is activated by TO901317, and Ras inhibitor,
farnesylthiosalicylic acid, reversed the phosphorylation of
ERK (Figure 4h and i), suggesting that Ras is involved in
LXR-mediated ERK activation.
TO901317 reduced UVB-induced hyperpigmentation in brown
guinea pig in vivo
Next, we examined the antimelanogenic effect of TO901317
in vivo using a UVB-induced hyperpigmentation model in
brown guinea pigs. As shown in Figure 5a, representative
photographs of dorsal skin showed that TO901317 (1%)
reduced hyperpigmentation when compared with the vehicle
treatment. To measure the degree of pigmentation, we
checked the L value (brightness index) with a chromameter.
The DL value of TO901317 group was significantly increased
than that of vehicle group, indicating the attenuation of
pigmentation (Figure 5b). Fontana–Masson staining of skin
tissue clearly showed that TO901317 markedly suppressed
UVB-induced melanin synthesis in the epidermal basal layer
(Figure 5c). Immunohistochemical staining of a melanocyte
marker protein, S-100, revealed that melanocyte count was
not affected by TO901317 (Figure 5d). These results demon-
strate that the activation of LXRs could have brightening effects
on UV-induced hyperpigmented skin in vivo.
DISCUSSION
Many research groups are focusing their efforts to elucidate
the regulation and the mechanism of skin pigmentation
with a goal of developing new treatment for pigmentary
disorders and hyperpigmentation-associated skin problems.
Through these efforts, a large number of biological and
chemical agents have been developed but only a few
were proved to be therapeutically effective and useful
because of adverse effects and cytotoxicity on skin cells.
Thus, it is necessary to further understand the mechanism
underlying pigmentation to develop more efficient and safe
antimelanogenic agents.
Recently, it has been reported that LXRs may have impor-
tant biological roles in the skin. LXRs induce lipid synthesis in
sebocytes and inhibit the expressions of cytokines and
metalloproteinases in skin-photoaging models (Man et al.,
2006; Chang et al., 2008; Hong et al., 2008). However, little is
known about the function of LXRs in melanocytes. Many
genes governed by LXRs are related to the regulation of
melanocytes; e.g., LXRs suppress the expression of IL-6,
which inhibits the growth of melanocytes (Oh et al., 1997).
Moreover, the expression of LXR was significantly upregulated
in perilesional skin of vitiligo patients compared with the
normal and unaffected regions, suggesting that LXRs might be
having an important role in the pathogenesis of pigmentary
disorders (Kumar et al., 2010). In this study, we showed that
both LXR isoforms are expressed and functional in murine
melanocytes, as determined by LXR expression and
TO901317-induced apoE expression (Figure 1a), confirming
the previous report (Zelcer and Tontonoz, 2006). Importantly,
we found that the activation of LXRs inhibited the expression
of melanogenic enzymes through the acceleration of ERK-
mediated MITF degradation, ultimately suppressing
melanogenesis. Most importantly, significant brightening
effects of the topical application of TO901317 were
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demonstrated in UVB-irradiated brown guinea pigs,
supporting that LXRs might be crucial intrinsic factors for the
regulation of melanogenesis.
Until now, more than 150 genes have been discovered to
affect the pigmentation of skin, hair, and eye (Bennett and
Lamoreux, 2003). Among them, a-MSH and ACTH were
identified as key intrinsic factors that induce pigmentation
(Yamaguchi and Hearing, 2009) through upregulating
tyrosinase, TRP-1, and TRP-2 via the mediation of MITF.
Recently, a report has revealed that serotonin induced
melanogenesis through serotonin receptor 2A (Lee et al.,
2011). In contrast, there are some biological factors that
interfere with pigmentation. Tumor necrosis factor-a and
IL-6 inhibit tyrosinase expression through MITF down-
regulation, and also several fatty acids increase tyrosinase
degradation (Solano et al., 2006). The activation of the MEK/
ERK/RSK-1 signaling pathway phosphorylates Ser 409 of MITF,
resulting in ubiquitin modification and proteasome-dependent
degradation (Busca` and Ballotti, 2000; Wu et al., 2000; Xu
et al., 2000). Similar to prior reports, recent studies have
revealed that a lot of depigmenting agents have inhibited the
expression of melanogenic enzymes through ERK-mediated
MITF proteolysis (Kim et al., 2003; Jang et al., 2009; Kwak
et al., 2011). We also found that the activation of LXRs
induced ERK phosphorylation, leading to the acceleration of
MITF degradation and subsequent inhibition of melanin
production. These results reflect that LXRs, as intrinsic
factors, may regulate the levels of MITF protein.
Interestingly, it is previously unreported that, in melano-
cytes, LXRs induced the activation of the MEK/ERK/RSK-1
signaling pathway at an early time. To our knowledge, there
have been no reports to date concerning the activation of the
MEK/ERK/RSK-1 signaling pathway by LXRs. After ERK or
RSK-1 is phosphorylated in cytoplasm, they translocate into
the nucleus, thereby inducing the phosphorylation of target
proteins, such as MITF. Thus, it is more likely that LXRs induce
the phosphorylation of the MEK/ERK/RSK-1 signaling cascade
in cytoplasm. Nuclear retention and localization of LXRa
and LXRb are differentially regulated. Unliganded LXRb is
exported from the nucleus, whereas unliganded LXRa is
retained in the nucleus (Pru¨fer and Boudreaux, 2007). A
recent study has revealed the cytosolic function of LXRs that
LXRb directly binds to ABCA1 on the plasma membrane,
inhibiting ATP binding to ABCA1 (Hozoji-Inada et al., 2011).
Furthermore, cytosolic LXRb directly interacts with activin
receptor-like kinase 1 (ALK-1) in the cytoplasm, a type I
TO (minutes)
α-MSH
TO
TO
p-ERK
p-ERK
PD
ERK
ERK
– + – +
++– –
– + – +
++– –
0 5 15 30
p-MEK
MEK
p-ERK
ERK
p-RSK
RSK
120
(–) α-MSH (+) α-MSH
(+) α-MSH
*****
100
80
60
40
M
el
an
in
 c
on
te
nt
s 
(%
)
M
el
an
in
 c
on
te
nt
s 
(%
)
M
el
an
in
 c
on
te
nt
s 
(%
)
20
0
PD
TO
PD ERK
p-ERK
TO–
–
–
+
+
–
+
+
–
–
–
+
+
–
– GW 22(R)HC
**
**
+
+
140
120
100
80
60
40
20
0
120
100
80
60
40
20
0
60 120
Figure 3. TO901317 (TO) activated the MEK/ERK/RSK signaling pathway in B16 cells. (a) Western blotting. B16 cells were treated with TO for the indicated time.
(b) Western blotting. B16 cells were treated with a-melanocyte-stimulating hormone (a-MSH) for 5 minutes in the presence or absence of TO. (c) Western blotting.
B16 cells were pretreated with 20mM PD98059 for 1 hour. Then, B16 cells were treated with TO for 5 minutes. (d) Measurement of melanin contents. B16 cells
were pretreated with 20mM PD98059 for 1 hour. Then, B16 cells were treated with TO for 72 hours in the presence or absence of a-MSH. (e) Measurement of
melanin contents and western blotting. B16 cells were treated with a-MSH for 72 hours in the presence of 5mM GW or 1mg ml 1 22(R)-hydroxycholesterol
(22(R)HC) for measurement of melanin contents and were treated with 5mM GW or 1mg ml 1 22(R)HC for 5 minutes for western blotting. Values represent the
mean±SE of three independent measurements. *Po0.05; **Po0.01. ERK, extracellular signal–regulated kinase; MEK, MAPK/ERK kinase; RSK, ribosomal S6
kinase.
CS Lee et al.
LXR Activation Inhibits Melanogenesis
www.jidonline.org 1067
TO (hours)
TO (hours)
TO (minutes)
p-MEK
p-ERK
ERK
MEK
0 5 15 30 60 120
0 0
MNT-1 MNT-1NHM NHM
4 8 12 24 0 24
Tyrosinase
Actin Actin
TO (μM)
ApoE
Actin
0 0 1
Pe
lle
t
Ly
sa
te
M
el
an
in
 c
on
te
nt
s 
(%
)
M
el
an
in
 c
on
te
nt
s 
(%
)
R
AS
 a
ct
ivi
ty
 (fo
ld
)
M
el
an
in
 c
on
te
nt
s 
(%
)5
120
100
80
60
40
20
0
120 35
30 TO
FTA
p-ERK
ERK
– + +
– – +25
20
15
10
5
100
80
60
40
20
0 0
TO TO (minutes)0 1 3 5 10 15
*
*
*
*
**
PD –
–
–
+ +
+
120
100
80
60
40
20
0
TO (μM)
TO (hours) 0 0.5 1 2 4 8 12
MiTF
0 1 5 TO (μM) 0 20
**
**
*
NHM MNT-1
24 48 72
Figure 4. The effects of TO901317 (TO) on melanogenesis and the extracellular signal–regulated kinase (ERK) signaling pathway in human melanocytes
and MNT-1 cells. (a) Western blotting. Normal human melanocytes (NHMs) were treated with 5mM TO for the indicated time. (b) The photograph of pellet
and lysates in NHMs and (c) melanin contents in NHMs and MNT-1 cells. On the fourth day, in the presence or absence of TO901317 after NHM or MNT-1
cell seeding, cells were washed with phosphate-buffered saline (PBS) one time and harvested. (d, f) Western blotting. NHMs or MNT-1 cells were treated
with TO for the indicated time. (g) Melanin contents. NHMs were pretreated with 20mM PD98059 for 1 hour. Then, NHMs were treated with 5mM TO for 96 hours.
(h) Ras activity assay. NHMs were treated with 5mM TO for the indicated time. The lysates were used for Ras activity assay as described in the Materials
and Methods. (i) Western blotting. NHMs were pretreated with 10mM farnesylthiosalicylic acid (FTA) for 1 hour. Then, NHMs were treated with 5mM TO
for 30 minutes. Values represent the mean±SE of three independent measurements. *Po0.05; **Po0.01. ApoE, apolipoprotein E; MEK, MAPK/ERK kinase;
MITF, microphthalmia-associated transcription factor.
Vehicle
Vehicle
–4
–3
–2
–1
0
1
2
Vehicle
F&
M
S-
10
0
TO
TO
Week0 21 3 4
*
(D
ark
) ←
 Δ
 L
 
va
lu
e 
→
 
(lig
ht)
TO
Vehicle TO
Ph
ot
og
ra
ph
Figure 5. TO901317 (TO) reduced UVB-induced hyperpigmentation in brown guinea pig. To determine the TO effect on pigmentation, TO (1%) was topically
applied to the dorsal skin areas once a day for 4 weeks from the day after the last UVB irradiation. The vehicle solution (PEG400/EtOH¼7:3) was applied as a
control. At least eight sites from four brown guinea pigs were used for a group. (a) Representative photographs of dorsal skin. (b) The degree of depigmentation was
determined by a chromameter (CR-300; Minolta, Osaka, Japan) once a week for 4 weeks. The DL value was calculated using the L value (brightness index)
measured with the chromameter follows: DL¼ L (at each day measured) L (at day 0). An increase in the DL value indicates a decrease in hyperpigmentation
induced by UV. (c) Fontana–Masson (F&M) staining of skin biopsies. (d) Immunohistochemical staining of skin biopsies for the detection of S-100 as a melanocyte
marker protein. *Po0.05.
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receptor in the transforming growth factor-b family, leading to
the regulation of ALK-1 downstream signaling pathway (Mo
et al., 2002). The receptor tyrosine kinases such as ALK-1
phosphorylate and activate MEK/ERK/RSK-1 proteins, resulting
in their translocation into the nucleus. Our study also
demonstrated the dominant role of LXRb in TO901317-
mediated antimelanogenesis through siRNA experiments.
Therefore, we speculate that LXRb could interact with
cytosolic proteins such as ALK-1, and then indirectly
phosphorylate MEK/ERK/RSK-1 proteins through other
kinases in the cytoplasm in early time course. To reveal the
detailed mechanism underlying LXR-induced ERK activation,
we examined the activation of Ras after TO901317 treatment.
TO901317 treatment induced transient activation of Ras and,
furthermore, Ras inhibitor, farnesylthiosalicylic acid, reversed
the ERK phosphorylation following TO901317, suggesting the
potential involvement of Ras in LXRb-mediated MEK/ERK
activation. However, we believe that further molecular
works are necessary to elucidate the events linking LXR
activation and Ras/MEK/ERK/RSK-1 activation.
In conclusion, we reported for the first time that the
activation of LXRs inhibited melanogenesis by downregulating
melanogenic enzymes through Ras- and ERK-induced MITF
degradation. Our findings provide a previously unreported
line of evidence supporting that LXRs may be key target
proteins for the treatment of pigmentary disorders.
MATERIALS AND METHODS
Materials
TO901317, a-MSH, ACTH, synthetic melanin, kojic acid, mushroom
tyrosinase, GW3965, and 22(R)HC were purchased from Sigma
(St Louis, MO). PD98059 was purchased from Calbiochem (San Diego,
CA). The antibodies against tyrosinase and actin were purchased from
Abcam (Cambridge, UK). Farnesylthiosalicylic acid as a Ras inhibitor
and the antibodies against TRP-1 and -2 were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The antibodies against phospho-
CREB, CREB, phospho-MEK, MEK, phospho-ERK, ERK, phospho-RSK,
and RSK were purchased from Cell Signaling Technology (Danvers,
MA), and the antibody against MITF was purchased from Proteintech
(Chicago, IL). The antibody against ApoE was purchased from Novus
Biologicals (Littleton, CO) and the antibody against S-100 was
purchased from Cell Marque (Rocklin, CA).
Cell cultures
B16 melanoma cells, DMEM, and FBS were purchased from the
ATCC (Manassas, VA). Cells were cultured in DMEM containing
10% fetal bovine serum, and incubated at 37 1C under 5% CO2
atmosphere. Normal human melanocytes from the neonatal
foreskin of darkly pigmented donor were purchased from Cascade
Biologics (#C-202–5C; Portland, OR) and cultured in Medium 254
(#M-254–500; Cascade Biologics) supplemented with Human
Melanocyte Growth Supplement 2 (#S-016-5; Cascade Biologics).
Melanocytes at passage numbers between 4 and 7 were used for the
experiments.
Cell viability assay
The viability of cultured cells was performed using CCK-8 (Cell Counting
Kit-8), as described by the manufacturer (DOJINDO, Tokyo, Japan).
Measurement of melanin contents
Cells were treated with indicated compound, and then incubated for
72 or 96 hours. After they were washed twice with phosphate-
buffered saline, cells were dissolved in 100ml of 1 N NaOH at
60 1C for 2 hours. Total melanin content was estimated by absorbance
at 405 nm and comparison made with a melanin standard curve using
synthetic melanin.
Mushroom tyrosinase activity assay
A cell-free assay system was used to investigate the direct effects of
TO901317 on tyrosinase activity. Briefly, 100ml of phosphate
buffer containing compound was mixed with 10 unit mushroom
tyrosinase, and 50ml of 0.03% tyrosine in deionized water was then
added. After incubation at 37 1C for 10 minutes, absorbance was
measured at 475 nm.
Reverse transcription–PCR
Total RNA was extracted from cell lysates using TRIzol reagent
(Invitrogen, Grand Island, NY), and complementary DNA was
prepared using a RT-premix (Bioneer, Seoul, South Korea) according
to the manufacturer’s instructions. Oligonucleotide primers were
purchased from Bioneer (Seoul, South Korea). The sequences of
PCR primers were: forward, 50-TCCATCAACCACCCCCACGAC-30
and reverse, 50-CAGCCAGAAAACACCCAACCT-30 for mouse LXRa;
forward, 50-TCGCCATCAACATCTTCTCAG-30 and reverse, 50-GTGT
GGTAGGCTGAGGTGTAA-30 for mouse LXRb; forward, 50-TCTGAC
CAGGTCCAGGAAGAG-30 and reverse, 50-AGCTGTTCCTCCAGCTC
CTTT-30 for mouse apoE; forward, 50-CAGAGGCACCAGGTAAAG
CA-30 and reverse, 50-GGATCCATCAAGCCCAAAAT-30 for mouse
MITF; forward, 50-ACCACAGTCCATGCCATCAC-30 and reverse,
50-TCCACCACCCTGTTGCTGTA-30 for mouse glyceraldehyde-3-
phosphate dehydrogenase. PCR products were separated by
electrophoresis on 1% agarose gels and detected under UV light.
Transfection of siRNA
The siRNA oligonucleotides against mouse LXRa, LXRb, and control
were purchased from Santa Cruz Biotechnology. B16 cells were
transfected with siRNA oligonucleotides using GenJet transfection
reagent (SignaGen, Gaithersburg, MD) according to the manufac-
turer’s instructions.
Western blotting
Cells were washed twice with cold phosphate-buffered saline, and
then lysed in ice-cold modified RIPA buffer (50 mM Tris-HCl, pH 7.4,
1% Nonidet P-40, 0.5% sodium deoxycholate, 150 mM NaCl) con-
taining protease inhibitors and phosphatase inhibitor cocktail set
(Calbiochem). Proteins were separated by SDS-PAGE and transferred
to nitrocellulose membranes. The membranes were incubated
with primary antibodies at 4 1C for 24 hours, then washed with
Tris-buffered saline, including 0.1% Tween-20, exposed to perox-
idase-conjugated secondary antibodies for 1 hour at room temperature,
washed, and then visualized using an Enhanced Chemiluminescence
Plus kit (Amersham Biosciences, Piscataway, NJ).
Ras activity assay
Ras activity was measured using a Ras Activation ELISA assay Kit
(Millipore, Billerica, CA). Briefly, normal human melanocytes were
treated with TO901317 for the indicated time and then lysed in lysis
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buffer. The supernatant was collected by microcentrifuge. After protein
concentration was calculated, the sample was used to detect Ras
activity using an assay Kit according to the manufacturer’s instructions.
UVB-induced hyperpigmentation model using brown guinea pig
Four brown guinea pigs weighingB500 g were purchased from Kiwa
Experimental Animal Laboratories (Wakayama, Japan), and housed
individually in temperature-controlled (23±3 1C) and relative humid-
ity (50±10%)–controlled rooms with a 12-hour light/dark cycle.
Groups of four animals were used for each experiment. After 1 week
of adaptation, the UVB-induced hyperpigmentation was performed
on the backs of brown guinea pigs, using methods slightly modified
from those reported by Yokota et al. (1998). All animal procedures for
this study were approved by the AmorePacific Institutional Animal
Care and Use Committee.
Fontana–Masson staining and immunohistochemistry for S-100
Histology skin biopsies were taken immediately after in vivo evalua-
tion by a biopsy punch and were fixed in 4% buffered formaldehyde
solution. The samples were embedded in paraffin wax, cut to a
thickness of 3mm, and stained using Fontana–Masson staining. The
Fontana–Masson staining was adapted from a method described
previously (Yokota et al., 1998). For S-100 immunohistochemistry,
tissue sections were deparaffinized with zylene and washed in
ethanol. After antigen unmasking using sodium citrate buffer, endo-
genous peroxidase activity was inhibited by 3% hydrogen peroxide.
Slides were then incubated with blocking solution for 1 hour at room
temperature. After removing the blocking solution, slides were
applied with S-100 primary antibody. After washing the slides, they
were incubated with secondary antibody (GBI, Mukileto, WA). Then,
slides were treated with aminoethylcarbazole to develop the sections.
Statistical analysis
Values were expressed as means±SE. Statistical comparisons
were made using Student’s t-test and analysis of variance test with
Minitab (State College, PA).
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